Before Tuesday’s opening bell, Medtronic (MDT) released its third quarter financial results. Here’s what the results mean for mutual fund investors.
Inside MDT's Results
MDT reported earnings of $977 million, or 98 cents per share, up from $762 million, or 75 cents per share, a year ago. Adjusted EPS was $1.01 – above analysts’ estimate of 97 cents.
Revenue increased to $4.318 billion from $4.163 billion last year. Analysts expected to see revenue of $4.25 billion.
Covidien Deal Will Keep Medtronic Diversified
At the end of January, Medtronic closed its $43 billion merger deal with Ireland-based Covidien. The deal will allow the company to re-incorporate in Ireland and will also provide the company with much needed diversification. This new diversification will partially offset the loss of market share in some of its businesses.
Mutual Funds to Watch
Investors interested in MDT may be interested in the funds listed below. These funds currently have the largest stakes in the company.
|VTSMX||Vanguard Total Stock Market Index||2.48%|
|VFIAX||Vanguard 500 Index||1.59%|
The Bottom Line
The funds listed above allow investors to gain exposure to MDT while remaining diversified. Investors interested in MDT may also be interested in St. Jude Medical (STJ) and Boston Scientific (BSX).